Previous close | 45.54 |
Open | 46.27 |
Bid | 45.41 x 200 |
Ask | 45.53 x 200 |
Day's range | 45.12 - 46.89 |
52-week range | 26.66 - 68.27 |
Volume | |
Avg. volume | 715,193 |
Market cap | 2.236B |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | 105.84 |
EPS (TTM) | 0.43 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 48.28 |
STAAR Surgical (NASDAQ:STAA) has had a great run on the share market with its stock up by a significant 64% over the...
LAKE FOREST, Calif., May 01, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.
LAKE FOREST, Calif., April 29, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.